Genetics of Ovarian Cancer (2nd Edition)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".
Deadline for manuscript submissions: 30 May 2026 | Viewed by 2161
Special Issue Editors
2. Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
3. AELIA Organization, 9th Km Thessaloniki-Thermi, 57001 Thessaloniki, Greece
4. Faculty of Medicine, Health and Social Care, Canterbury Christ Church University, Canterbury, UK
5. School of Cancer and Pharmaceutical Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK
6. Kent and Medway Medical School, University of Kent, Canterbury, UK
7. Department of Research and Innovation, Medway NHS Foundation Trust, Gillingham, UK
Interests: prostate cancer; renal cancer; ovarian cancer; homologous recombination of DNA; PARP inhibitors; cervical cancer; carcinoma of unknown primary; colorectal cancer; cancer and autoimmune diseases; biomarkers
Special Issues, Collections and Topics in MDPI journals
2. Department of Oncology, Guy's and St Thomas' Hospital, London SE1 9RT, UK
3. School of Cancer & Pharmaceutical Sciences, King's College London, Strand, London WC2R 2LS, UK
Interests: novel MRI techniques; ovarian cancer;prostate cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is a continuation of our previous Special Issue, “Genetics of Ovarian Cancer” (https://www.mdpi.com/journal/cancers/special_issues/F58V953794).
Epithelial ovarian cancers (EOCs), which are characterized by recurrent, persistent disease and the rapid acquisition of chemotherapy resistance, remain one of the most lethal gynaecological malignancies. DNA damage is one of the hallmarks of cancer. Among EOCs, the high-grade serous subtype harbours a defect in at least one DNA damage response (DDR) pathway. Defective DDR results from a variety of lesions affecting homologous recombination (HR) and nonhomologous end joining (NHEJ) for double-strand breaks, base excision repair (BER), and nucleotide excision repair (NER) for single-strand breaks and mismatch repair (MMR).
We are pleased to invite you to submit manuscripts that help the community to understand that DDR pathways are essential in order to optimize the therapeutic choices, as well as highlight the importance of designing biomarker-driven clinical trials. Poly(ADP-ribose) polymerase (PARP) inhibitors are a well-established treatment for EOCs. Moreover, combinations of PARP inhibitors with drugs that inhibit HR may sensitize EOCs with a primary or secondary HR proficiency to PARP inhibitors and potentially expand their use beyond HR-deficient ovarian cancers. Regarding this, PARP inhibitors may be combined separately with anti-angiogenics and immune checkpoint inhibitors as well as with phosphoinositide 3-kinase (PI3K), protein kinase B (AKT), mammalian target of rapamycin (mTOR), WEE1, mitogen-activated protein kinase (MEK), and cyclin-dependent kinase (CDK) 4/6 inhibitors, or even with standard chemotherapy.
Through this Special Issue, we aim to elucidate the mechanisms implicated in DDR, the genomic analysis of ovarian cancer, and therapeutics of PARP inhibitors, and predictive biomarkers.
This Special Issue welcomes manuscripts whose scope includes, but is not limited to, the following topics:
- EOC risk assessment in the era of next-generation sequencing;
- Predictive and prognostic biomarkers in EOC;
- DNA damage response;
- PARP inhibitors in EOC;
- PARP inhibitors in combination with other therapies;
- Immunotherapy in EOC;
- Chemoresistance;
- Regression.
We look forward to receiving your contributions.
Dr. Stergios Boussios
Dr. Sola Adeleke
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- epithelial ovarian cancer
- genomics
- epigenetics
- translational research
- biomarkers
- DNA damage response
- PARP inhibitors
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
